{"id":25919,"date":"2025-08-27T06:34:07","date_gmt":"2025-08-27T06:34:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/25919\/"},"modified":"2025-08-27T06:34:07","modified_gmt":"2025-08-27T06:34:07","slug":"association-between-serum-albumin-to-creatinine-ratio-and-non-alcoholic-fatty-liver-disease-a-longitudinal-cohort-study-in-non-obese-chinese-individuals-bmc-gastroenterology","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/25919\/","title":{"rendered":"Association between serum albumin to creatinine ratio and non-alcoholic fatty liver disease: a longitudinal cohort study in non-obese Chinese individuals | BMC Gastroenterology"},"content":{"rendered":"
  • \n

    Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537\u201364.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, et al. A global action agenda for turning the tide on fatty liver disease. Hepatol Baltim Md. 2024;79:502\u201323.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ren T-Y, Fan J-G. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol. 2021;18:289\u201390.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u201352.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, St\u00e5l P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. Hepatol Commun. 2018;2:48\u201357.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71:382\u201390.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165:1025\u201340.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Sun D-Q, Wu S-J, Liu W-Y, Wang L-R, Chen Y-R, Zhang D-C, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: A cross-sectional and longitudinal study. BMJ Open. 2016;6:e013781.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Lou T-W, Yang R-X, Fan J-G. The global burden of fatty liver disease: the major impact of China. Hepatobiliary Surg Nutr. 2024;13:119\u201323.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wu N, Liu T, Tian M, Liu C, Ma S, Cao H, et al. Albumin, an interesting and functionally diverse protein, varies from \u2018native\u2019 to \u2018effective\u2019 (review). Mol Med Rep. 2023;29:24.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    As L, La I. Assessment of glomerular filtration rate in health and disease: a state of the Art review. Clin Pharmacol Ther. 2017;102.<\/p>\n<\/li>\n

  • \n

    Niu Y, Zhang W, Zhang H, Li X, Lin N, Su W, et al. Serum creatinine levels and risk of nonalcohol fatty liver disease in a middle-aged and older Chinese population: A cross-sectional analysis. Diabetes Metab Res Rev. 2022;38:e3489.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    M\u00e4nnist\u00f6 VT, Salomaa V, F\u00e4rkkil\u00e4 M, Jula A, M\u00e4nnist\u00f6 S, Erlund I, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver Int Off J Int Assoc Study Liver. 2021;41:2590\u2013600.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156\u201362.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cen J, Han Y, Liu Y, Hu H. Evaluated glomerular filtration rate is associated with non-alcoholic fatty liver disease: a 5-year longitudinal cohort study in Chinese non-obese people. Front Nutr. 2022;9:916704.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Li S, Xie X, Zeng X, Wang S, Lan J. Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure. Clin Transl Sci. 2023;16:2345\u201355.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Turkyilmaz E, Ozkalayci F, Birdal O, Karagoz A, Tanboga IH, Tanalp AC, et al. Serum albumin to creatinine ratio and short-term clinical outcomes in patients with ST-elevation myocardial infarction. Angiology. 2022;73:809\u201317.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Dai H, Liu L, Xu W. Association of albumin-to-creatinine ratio with diabetic retinopathy among US adults (NHANES 2009\u20132016). Endocrinol Diabetes Metab. 2025;8:e70029.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148:1606\u201335.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kim K-S, Hong S, Han K, Park C-Y. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384:e076388.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023;148:1636\u201364.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Steventon JJ, Trueman RC, Ma D, Yhnell E, Bayram-Weston Z, Modat M, et al. Longitudinal in vivo MRI in a huntington\u2019s disease mouse model: global atrophy in the absence of white matter microstructural damage. Sci Rep. 2016;6:32423.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhang N, Hu X, Zhang Q, Bai P, Cai M, Zeng TS, et al. Non-high-density lipoprotein cholesterol: high-density lipoprotein cholesterol ratio is an independent risk factor for diabetes mellitus: results from a population-based cohort study. J Diabetes. 2018;10:708\u201314.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    ZENG MD, LI YM, CHEN CW, LU LG, FAN JG, WANG BY, et al. Guidelines for the diagnosis and treatment of alcoholic liver disease*. J Dig Dis. 2008;9:113\u20136.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Cao C, Mo Z, Han Y, Luo J, Hu H, Yang D, et al. Association between Alanine aminotransferase to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: a retrospective cohort study in lean Chinese individuals. Sci Rep. 2024;14:6056.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Stevens LA, Claybon MA, Schmid CH, Chen J, Horio M, Imai E, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011;79:555\u201362.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539\u201353.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Dong MH, Bettencourt R, Barrett-Connor E, Loomba R. Alanine aminotransferase decreases with age: the rancho Bernardo study. PLoS ONE. 2010;5:e14254.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhao W, Zhang J, You Y, Man Q, Li H, Wang C, et al. [epidemiologic characteristics of dyslipidemia in people aged 18 years and over in china]. Zhonghua Yu Fang Yi Xue Za Zhi. 2005;39:306\u201310.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Triozzi JL, Richardson PA, Gregg LP, Navaneethan SD. Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease. Nephrol Dial Transpl. 2021;36:1546\u20138.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wax Y. Collinearity diagnosis for a relative risk regression analysis: an application to assessment of diet-cancer relationship in epidemiological studies. Stat Med. 1992;11:1273\u201387.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163\u2013194.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch JJF, et al. Contribution of Cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the biomarcare project. BMC Med. 2020;18:300.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Wu L, Zhang M, Hu H, Wan Q. Elevated gamma-glutamyl transferase has a non-linear association with incident non-alcoholic fatty liver disease in the non-obese Chinese population: A secondary retrospective study. Lipids Health Dis. 2021;20:142.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. Association between soft drink consumption and mortality in 10 European countries. JAMA Intern Med. 2019;179:1479.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Keidel D, Anto JM, Basaga\u00f1a X, Bono R, Burte E, Carsin A-E, et al. The role of socioeconomic status in the association of lung function and air Pollution\u2014A pooled analysis of three adult ESCAPE cohorts. Int J Environ Res Public Health. 2019;16:1901.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Groenwold RHH, White IR, Donders ART, Carpenter JR, Altman DG, Moons KGM. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. Can Med Assoc J. 2012;184:1265\u20139.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377\u201399.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Bland JM, Altman DG. Statistics notes: multiple significance tests: the bonferroni method. BMJ. 1995;310:170\u2013170.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Zhu F, Chen C, Zhang Y, Chen S, Huang X, Li J, et al. Elevated blood mercury level has a non-linear association with infertility in U.S. Women: data from the NHANES 2013\u20132016. Reprod Toxicol. 2020;91:53\u20138.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321:602.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kawaguchi K, Sakai Y, Terashima T, Shimode T, Seki A, Orita N, et al. Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. Med (Baltim). 2021;100:e26835.<\/p>\n

    CAS<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, et al. Association of serum albumin levels and Long-Term prognosis in patients with Biopsy-Confirmed nonalcoholic fatty liver disease. Nutrients. 2023;15:2014.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic fatty liver disease and the kidney: a review. Biomedicines. 2021;9:1370.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Moon JS, Lee JE, Yoon JS. Variation in serum creatinine level is correlated to risk of type 2 diabetes. Endocrinol Metab. 2013;28:207.<\/p>\n


    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Yang M, Geng C-A, Liu X, Guan M. Lipid disorders in NAFLD and chronic kidney disease. Biomedicines. 2021;9:1405.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Belinskaia DA, Voronina PA, Shmurak VI, Jenkins RO, Goncharov NV. Serum albumin in health and disease: esterase, antioxidant, transporting and signaling properties. Int J Mol Sci. 2021;22:10318.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Claudel SE, Verma A. Cardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care. Cell Metab. 2023;35:2104\u20136.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-Kidney-Metabolic health: A scientific statement from the American heart association. Circulation. 2023;148:1982\u20132004.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Javaid A, Hariri E, Ozkan B, Lang K, Khan SS, Rangaswami J, et al. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A Case-Based narrative review. Am J Med Open. 2025;13:100089.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Ao N, Du J, Jin S, Suo L, Yang J. The cellular and molecular mechanisms mediating the protective effects of sodium\u2013glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease. Diabetes Obes Metab. 2025;27:457\u201367.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Hameed I, Hayat J, Marsia S, Samad SA, Khan R, Siddiqui OM, et al. Comparison of sodium-glucose cotransporter-2 inhibitors and Thiazolidinediones for management of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2023;47:102111.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes. 2019;10:114\u201332.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801\u20138.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Jin Z, Yuan Y, Zheng C, Liu S, Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37:108558.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor Ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246\u201355.<\/p>\n

    CAS<\/a>\u00a0
    \n     PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Benjamin S, Ramanjaneya M, Butler AE, Janjua I, Paramba F, Palaki J, et al. Dapagliflozin, as Add-on therapy in type 2 diabetes patients, is associated with a reduction in albuminuria and serum transaminase levels. Front Clin Diabetes Healthc. 2021;2:733693.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Pan X, Xie X, Peng H, Cai X, Li H, Hong Q, et al. Risk prediction for Non-alcoholic fatty liver disease based on biochemical and dietary variables in a Chinese Han population. Front Public Health. 2020;8:220.<\/p>\n

    PubMed<\/a>\u00a0
    \n     PubMed Central<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n

  • \n

    Song SJ, Lai JC-T, Wong GL-H, Wong VW-S, Yip TC-F. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54\u20136.<\/p>\n

    PubMed<\/a>\u00a0
    \n
    \n Google Scholar<\/a>\u00a0\n <\/p>\n<\/li>\n","protected":false},"excerpt":{"rendered":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537\u201364. CAS\u00a0…\n","protected":false},"author":2,"featured_media":25920,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[21344,21346,18,1910,135,1912,19,1911,17,10610,21347,21345],"class_list":{"0":"post-25919","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-cohort-study","9":"tag-cox-proportional-hazards-regression","10":"tag-eire","11":"tag-gastroenterology","12":"tag-health","13":"tag-hepatology","14":"tag-ie","15":"tag-internal-medicine","16":"tag-ireland","17":"tag-non-alcoholic-fatty-liver-disease","18":"tag-non-linear","19":"tag-serum-albumin-to-creatinine-ratio"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/25919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=25919"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/25919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/25920"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=25919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=25919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=25919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}